Description: A clinical stage biopharmaceutical company developing best-in-class novel therapeutics to relieve the suffering of patients with neurodegenerative diseases, psychiatric disorders and pain.
XWPharma employs the following strategies across all of our programs to increase the odds that our internally discovered medicines will succeed in clinical testing and commercialization.
Narcolepsy is a life-long disease characterized by fragmented sleep which manifests primarily as excessive daytime sleepiness (EDS) and cataplexy, a sudden and uncontrollable muscle weakness or paralysis. Narcolepsy is considered an orphan disease in the US affecting between an estimated 165,000 and 185,000 people. 2,3 GABA B agonists indicated for treatment of narcolepsy currently represent close to $2.0 billion in US annual sales. Non-motor Symptoms of Parkinson’s disease , especially sleep disorders,
Major depressive disorder (MDD) and chronic pain are both highly prevalent and debilitating conditions. Over 264 million people worldwide suffer from MDD and one-third of these patients are considered treatment-resistant, failing 2 or more antidepressants. 1 One in 5 (1.5 billion) people around the world experience chronic pain while over 20 million people in the US alone suffer from chronic pain that frequently limits life and work activities. 2,3 Despite therapies available, significant unmet needs remain